In response to a number of articles in the press over summer querying the relevance of and need for a global antimalarial subsidy planned by the Affordable Medicines Facility, malaria (AMFm), the MMV Access team and our partners in Uganda wrote a comment to The Lancet. “Cost is killing patients: subsidising effective antimalarials” has just been published, a month before the AMFm announces the first set of countries that will benefit from a global antimalarial subsidy.